Changes to the Code
S. 4472 · Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 · Engrossed The official text as one chamber (House or Senate) passed it.
Passed the Senate · step 3 of 5
42 U.S.C. § 280g–7b HHS public-private partnership for rare neurodegenerative diseases
+2 −2Shown
2 changes the bill asks for here, 2 carried out
- Carried out:
in subsection (a), in the matter preceding paragraph (1), by striking
amytrophic
and insertingamyotrophic
; and - Carried out:
in subsection (b)(3)(A)(iii), by striking
rational
.
§ 280g–7b(a)
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| § 280g–7b. HHS public-private partnership for rare neurodegenerative diseases | § 280g–7b. HHS public-private partnership for rare neurodegenerative diseases | |||
| (a) | (a) Establishment | (a) Establishment | ||
| Not later than one year after December 23, 2021, the Secretary of Health and Human Services (referred to in this section as the “Secretary”) shall establish and implement a Public-Private Partnership for Neurodegenerative Diseases between the National Institutes of Health, the Food and Drug Administration, and one or more eligible entities (to be known and referred to in this section as the “Partnership”) through cooperative agreements, contracts, or other appropriate mechanisms with such eligible entities, for the purpose of advancing the understanding of neurodegenerative diseases and fostering the development of treatments for | Not later than one year after December 23, 2021, the Secretary of Health and Human Services (referred to in this section as the “Secretary”) shall establish and implement a Public-Private Partnership for Neurodegenerative Diseases between the National Institutes of Health, the Food and Drug Administration, and one or more eligible entities (to be known and referred to in this section as the “Partnership”) through cooperative agreements, contracts, or other appropriate mechanisms with such eligible entities, for the purpose of advancing the understanding of neurodegenerative diseases and fostering the development of treatments for [inserted: amyotrophic] lateral sclerosis and other rare neurodegenerative diseases. The Partnership shall— | |||
| (a)(1) | (1) | (1) | ||
| establish partnerships and consortia with other public and private entities and individuals with expertise in amyotrophic lateral sclerosis and other rare neurodegenerative diseases for the purposes described in this subsection; | establish partnerships and consortia with other public and private entities and individuals with expertise in amyotrophic lateral sclerosis and other rare neurodegenerative diseases for the purposes described in this subsection; | |||
| (a)(2) | (2) | (2) | ||
| focus on advancing regulatory science and scientific research that will support and accelerate the development and review of drugs for patients with amyotrophic lateral sclerosis and other rare neurodegenerative diseases; and | focus on advancing regulatory science and scientific research that will support and accelerate the development and review of drugs for patients with amyotrophic lateral sclerosis and other rare neurodegenerative diseases; and |
§ 280g–7b(b)Eligible entity(3)–(4)
(a)(3)–(b)(3) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (3)(A)(ii) | (ii) | (ii) | ||
| to identify molecular targets for neurodegenerative diseases; and | to identify molecular targets for neurodegenerative diseases; and | |||
| (3)(A)(iii) | (iii) | (iii) | ||
| to increase efficiency, predictability, and productivity of clinical development of therapies, including advancement of | to increase efficiency, predictability, and productivity of clinical development of therapies, including advancement of therapeutic development and establishment of clinical trial networks; and | |||
| (3)(B) | (B) | (B) | ||
| securing funding for the Partnership from Federal and non-Federal governmental sources, foundations, and private individuals; and | securing funding for the Partnership from Federal and non-Federal governmental sources, foundations, and private individuals; and | |||
| (4) | (4) | (4) | ||
| provides an assurance that the entity will not accept funding for a Partnership project from any organization that manufactures or distributes products regulated by the Food and Drug Administration unless the entity provides assurances in its agreement with the Secretary that the results of the project will not be influenced by any source of funding. | provides an assurance that the entity will not accept funding for a Partnership project from any organization that manufactures or distributes products regulated by the Food and Drug Administration unless the entity provides assurances in its agreement with the Secretary that the results of the project will not be influenced by any source of funding. |
Rest of § 280g–7b unchanged